Latanoprost Viatris

Latanoprost, the active ingredient in Latanoprost Viatris, is a prostaglandin analog presented as an ophthalmic solution for ocular (topical) use. It treats primary open-angle glaucoma and ocular hypertension by lowering intra‑ocular pressure in affected patients.

GNH USA supplies Latanoprost Viatris as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Latanoprost is used in the management of ocular conditions that require reduction of intra‑ocular pressure.

Primary open‑angle glaucoma: lowers intra‑ocular pressure, helping to preserve visual field and delay disease progression. Ocular hypertension: reduces elevated eye pressure to prevent conversion to glaucoma. Elevated intra‑ocular pressure (any cause): provides consistent pressure reduction to protect optic nerve health.

Latanoprost may cause ocular and systemic reactions after topical administration.

Common Side Effects: - Conjunctival hyperemia (eye redness) - Increased eyelash length and thickness - Iris pigmentation darkening - Eye irritation or foreign‑body sensation - Blurred vision - Mild pruritus of the eyelid

Serious or Rare Side Effects: - Severe allergic reaction (e.g., angio‑edema, anaphylaxis) - Ocular inflammation such as uveitis or keratitis - Paradoxical increase in intra‑ocular pressure - Corneal edema or endothelial dysfunction - Vision loss or sudden visual disturbances - Systemic hypersensitivity (e.g., rash, fever)

Before initiating therapy, clinicians should evaluate patient history and monitor ocular response.

Assess baseline intra‑ocular pressure: confirm need for pressure‑lowering therapy. Monitor iris color changes: document pigmentation at each visit. Evaluate for history of uveitis or ocular infection: avoid use during active inflammation. Avoid concurrent use with other prostaglandin analog eye drops: risk of additive effects. Pregnancy and lactation: safety not established; use only if benefit outweighs risk. Store at ambient temperature: keep bottle tightly closed, protect from light and moisture.

Latanoprost may interact with other ophthalmic agents, altering efficacy or safety.

Major Interactions (Avoid): - Concomitant prostaglandin analog eye drops: additive pressure‑lowering effect may cause hypotony. - Topical ocular steroids: may diminish Latanoprost's IOP‑lowering action. - Anticholinergic eye drops: potential for reduced drug absorption.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory eye drops: may increase ocular irritation. - Systemic carbonic anhydrase inhibitors: additive IOP reduction, monitor pressure. - Antihistamine eye drops: possible decreased efficacy, observe pressure response.